Physician profile
Jairo Cruz
NPI 1245295567
$1,797.48
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $591 · 2024: $27.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $456.36 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $361.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.47 | 2019-2020 | |
| Genentech USA, INC. | $141.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $135.47 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Amgen INC. | $124.99 | 2019 | |
| Pfizer INC. | $112.16 | 2019-2020 | |
| Abbott Laboratories | $27.15 | 2024 | Cardiomems |
| Akcea Therapeutics, INC. | $21.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.47 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairo Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.